In particular, patients with advanced fibrosis (F3) or cirrhosis (F4), have a substantial residual risk of HCC that remains after viral eradication.

Sep 23, 2024 · Achieving a sustained virologic response (SVR) through direct-acting antivirals for hepatitis C virus (HCV) infection significantly reduces the long-term risk of hepatocellular carcinoma (HCC), particularly in patients with advanced fibrosis (F3) or cirrhosis (F4).

Eradication of HCV by antiviral treatment reduces but does not eliminate the risk of hepatocellular carcinoma (HCC). In particular, patients with advanced brosis (F3) or cirrhosis (F4), have a. substantial residual risk of HCC that remains after viral eradication.

However, individual patients carry a variety of risk factors that modify their HCC risk after SVR, including most importantly fibrosis stage (F3 versus F4) but also age, sex, albumin level, genotype, and components of the FIB-4 score like platelet count and AST/ALT. 16,17 A tissue-based transcriptome signature has also been shown to accurately ...

Feb 24, 2022 · The HCC risk model. GAF criteria based on gamma‐glutamyl transpeptidase, AFP, and FIB‐4 index at any point after SVR can help identify patients at negligible risk of developing HCC who may be able to discontinue HCC surveillance. Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; DAA, direct‐acting antiviral.

Promising strategies for estimating HCC risk include simplified scoring systems (such as fibrosis-4), liver elastography and multivariable HCC risk calculators. Such tools may enable risk stratification and individualised, risk-based surveillance …

Patients with baseline F3‐4 fibrosis treated with new oral direct‐acting antivirals who had reached a SVR were regularly followed as part of the HCC surveillance strategy. Six models were applied: Pons, aMAP, Ioannou, HCC risk, Alonso and Semmler.

HCV eradication by antiviral treatment reduces but does not eliminate HCC risk. Patients with established cirrhosis require HCC surveillance "indefinitely" after sustained virologic response (SVR) because they appear to have a high risk of HCC even many years after SVR.

Dec 20, 2018 · We designed a Markov cohort, state-transition model to evaluate the cost effectiveness of biannual and annual surveillance for HCC in 50-year-old patients with advanced fibrosis (F3) or compensated cirrhosis (F4) who achieved SVR for chronic HCV infection through comparing strategies of screen-all patients using abdominal ultrasound and screen ...

Sustained virologic response (SVR), or cure, occurs in roughly 98% of patients with compensated liver disease. However, there are still 2 patient subgroups that have lower SVR rates: patients with decompensated cirrhosis (ie, Child-Pugh B or C cirrhosis) …